Metabolism, pharmacokinetics, and bioavailability of yuanhuacine in rat using LC–MS
Authors:
- 10 November 2022
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 37 (2) , e5540
Abstract
Yuanhuacine is a Daphne‐type diterpene ortho‐ester and is one of the main active ingredients of genkwa flos. Anticancer activity of yuanhuacine has been well investigated in various tumor cells and animal models, but information on metabolism and pharmacokinetics is limited. The aims of the present study were to investigate the metabolic and pharmacokinetic profiles of yuanhuacine in rat. The metabolic profile of yuanhuacine was obtained from rat plasma, urine, and feces using ultra‐high‐performance liquid chromatography‐quadrupole‐time‐of‐flight mass spectrometry. A total of seven metabolites were detected, and the proposed metabolic pathways involved oxidation and glucuronidation. A simple and sensitive ultra‐high‐performance liquid chromatography‐tandem mass spectrometry method was developed for the determination of yuanhuacine in rat plasma. The linear range of yuanhuacine was 1–1000 ng/ml (R2 = 0.998). The intra‐ and inter‐precision (coefficient of variation %) of the assay was 3.86–6.18% and 2.65–5.75%, respectively, and the intra‐ and inter‐accuracy (relative error %) was −3.83–4.77% and −3.03–5.11%, respectively. The extraction recovery, matrix effect, stability, and incurred sample reanalysis of yuanhuacine were within acceptable levels. The established method was validated and successfully applied to the preclinical pharmacokinetic study of yuanhuacine. The absolute oral bioavailability of yuanhuacine was calculated as 1.14%, and it reached the maximum plasma concentration of 28.21 ± 2.79 ng/ml in rat plasma at 2 h in the oral dosing group. The apparent volume of distribution of intravenous and intragastric administrations was 26.07 ± 6.45 and 21.83 ± 3.54 L/kg, respectively. The half‐life of elimination of yuanhuacine was 9.64 ± 1.53 h in the intravenous dosing group.Keywords
Funding Information
- National Natural Science Foundation of China (82074272, 82104541)
- Program of Shanghai Academic Research Leader (21XD1403400)
- Science and Technology Commission of Shanghai Municipality (20S21900300)
This publication has 17 references indexed in Scilit:
- A dynamic map for learning, communicating, navigating and improving therapeutic developmentNature Reviews Drug Discovery, 2017
- Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancerExpert Opinion on Drug Metabolism & Toxicology, 2017
- Daphnane and Phorbol Diterpenes, Anti-neuroinflammatory Compounds with Nurr1 Activation from the Roots and Stems of Daphne genkwaBiological and Pharmaceutical Bulletin, 2017
- Validation and Application of an Ultra High-Performance Liquid Chromatography Tandem Mass Spectrometry Method for Yuanhuacine Determination in Rat Plasma after Pulmonary Administration: Pharmacokinetic Evaluation of a New Drug Delivery SystemMolecules, 2016
- Daphnane Diterpenes from Daphne genkwa Activate Nurr1 and Have a Neuroprotective Effect in an Animal Model of Parkinson’s DiseaseJournal of Natural Products, 2016
- Pharmacokinetics, tissue distribution, and metabolism of novel DNA topoisomerase I inhibitor yuanhuacine in rabbitXenobiotica, 2009
- Metabolic activation of carboxylic acidsExpert Opinion on Drug Metabolism & Toxicology, 2008
- Preparation of yuanhuacine and relative daphne diterpene esters from Daphne genkwa and structure–activity relationship of potent inhibitory activity against DNA topoisomerase IBioorganic & Medicinal Chemistry, 2006
- Novel diterpenoids with potent inhibitory activity against endothelium cell HMEC and cytotoxic activities from a well-known TCM plant Daphne genkwaBioorganic & Medicinal Chemistry, 2005
- The effects of Genkwadaphnin and Gnidilatidin on the growth of P-388, L-1210 leukemia and KB carcinoma cells in VitroEuropean Journal of Cancer and Clinical Oncology, 1986